News

The new approval by the FDA increases the patient population which can be treated with the drug which is already approved for the treatment of adults with gastroesophageal

Vegenics has been set up to develop and commercialize the intellectual property and technology of the Ludwig Institute for Cancer (LICR) and Licentia relating to molecules known as

Bridgetech will have the right to manufacture and distribute these products throughout the Peoples Republic of China, Hong Kong, Macau and Taiwan. Bridgetech will also receive rights to

The additional eight weeks gave patients a greater chance of being successfully treated for chronic hepatitis C and also lowered the relapse rate after treatment. A total of

ALN-RSV01 is being evaluated for the treatment of respiratory syncytial virus (RSV) infection and is the first RNAi therapeutic in human clinical development for an infectious disease. Alnylam

CAIV-T, MedImmune’s latest generation of its FluMist nasal spray, was shown to be 55% more effective than the traditional shot in reducing influenza in children six months to

In the phase I study, patients are randomized to receive either oral treatment with R1626 or placebo for 14 days with 14 days of follow-up. Preliminary data were

Valopicitabine (NM283) 200mg/day demonstrated comparable antiviral activity to the results obtained in the 800mg/day-containing arms in a preliminary analysis of an ongoing phase IIb clinical trial in treatment-naive

The results demonstrate that Albuferon (albumin-interferon alpha 2b) in combination with ribavirin was safe, well tolerated and showed robust antiviral activity. The data were presented at the 41st